Subcutaneous Nanotherapy Repurposes the Immunosuppressive Mechanism of Rapamycin to Enhance Allogeneic Islet Graft Viability

Researchers demonstrated that subcutaneous delivery via poly(ethylene glycol)-b-poly(propylene sulfide) polymersome nanocarriers significantly altered rapamycin’s cellular biodistribution to repurpose its mechanism of action for tolerance, instead of immunosuppression, and minimize side effects.